Literature DB >> 26244137

Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard.

Deniz Yalman1, Ugur Selek1.   

Abstract

Entities:  

Year:  2015        PMID： 26244137      PMCID： PMC4499657          DOI： 10.3978/j.issn.2305-5839.2015.06.23

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  26 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  The 30- versus 90-day operative mortality after pulmonary resection.

Authors:  Ayesha S Bryant; Kyle Rudemiller; Robert J Cerfolio
Journal:  Ann Thorac Surg       Date:  2010-06       Impact factor: 4.330

Review 3.  Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.

Authors:  Francesca Soldà; Mark Lodge; Sue Ashley; Alastair Whitington; Peter Goldstraw; Michael Brada
Journal:  Radiother Oncol       Date:  2013-10-12       Impact factor: 6.280

Review 4.  Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned.

Authors:  Joe Y Chang; Andrea Bezjak; Françoise Mornex
Journal:  J Thorac Oncol       Date:  2015-04       Impact factor: 15.609

5.  Stereotactic ablative radiotherapy: what's in a name?

Authors:  Billy W Loo; Joe Y Chang; Laura A Dawson; Brian D Kavanagh; Albert C Koong; Suresh Senan; Robert D Timmerman
Journal:  Pract Radiat Oncol       Date:  2011-01-14

6.  Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.

Authors:  Naomi E Verstegen; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Radiother Oncol       Date:  2011-11-05       Impact factor: 6.280

7.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

8.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer.

Authors:  Frank J Lagerwaard; Cornelis J A Haasbeek; Egbert F Smit; Ben J Slotman; S Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

9.  Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery.

Authors:  John Varlotto; Achilles Fakiris; John Flickinger; Laura Medford-Davis; Adam Liss; Julia Shelkey; Chandra Belani; Jill DeLuca; Abram Recht; Neelabh Maheshwari; Robert Barriger; Nengliang Yao; Malcolm DeCamp
Journal:  Cancer       Date:  2013-04-19       Impact factor: 6.860

10.  Natural history of stage I non-small cell lung cancer: implications for early detection.

Authors:  Dan J Raz; Jason A Zell; S-H Ignatius Ou; David R Gandara; Hoda Anton-Culver; David M Jablons
Journal:  Chest       Date:  2007-05-15       Impact factor: 9.410
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.